Vinicius Rocha-Santos

Vinicius Rocha-Santos

Auto-generated profile, based on publicly available information

Vinicius Rocha-Santos

Universidade de São Paulo, Brazil

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
WAWellington Andraus
Wellington Andraus
Francisco TustumiFrancisco Tustumi
Francisco Tustumi
JJJosé Donizeti de Meira Junior
José Donizeti de Meira Junior
RPRafael Soares Nunes Pinheiro
Rafael Soares Nunes Pinheiro
DWDaniel Reis Waisberg
Daniel Reis Waisberg
LDLuiz Augusto Carneiro D’albuquerque
Luiz Augusto Carneiro D’albuquerque
Intrahepatic cholangiocarcinoma (ICC) is a relatively uncommon but highly aggressive primary liver cancer that originates within the liver. The aim of this study is to review the molecular profile of intrahepatic cholangiocarcinoma and its implications for prognostication and decision-making. This comprehensive characterization of ICC tumors sheds light on the disease’s underlying biology and offers a foundation for more personalized treatment strategies. This is a narrative review of the prognostic and therapeutic role of the molecular profile of ICC. Knowing the molecular profile of tumors helps determine prognosis and support certain target therapies. The molecular panel in ICC helps to select patients for specific therapies, predict treatment responses, and monitor treatment responses. Precision medicine in ICC can promote improvement in prognosis and reduce unnecessary toxicity and might have a significant role in the management of ICC in the following years. The main mutations in ICC are in tumor protein p53 (TP53), Kirsten rat sarcoma virus (KRAS), isocitrate dehydrogenase 1 (IDH1), and AT-rich interactive domain-containing protein 1A (ARID1A). The rate of mutations varies significantly for each population. Targeting TP53 and KRAS is challenging due to the natural characteristics of these genes. Different stages of clinical studies have shown encouraging results with inhibitors of mutated IDH1 and target therapy for ARID1A downstream effectors. Fibroblast growth factor receptor 2 (FGFR2) fusions are an important target in patients with ICC. Immune checkpoint blockade can be applied to a small percentage of ICC patients. Molecular profiling in ICC represents a groundbreaking approach to understanding and managing this complex liver cancer. As our comprehension of ICC’s molecular intricacies continues to expand, so does the potential for offering patients more precise and effective treatments. The integration of molecular profiling into clinical practice signifies the dawn of a new era in ICC care, emphasizing personalized medicine in the ongoing battle against this malignancy.

1 May 2004 in Transplantation Proceedings
Verified
Journal Article
Closed access
TBT Bacchella
T Bacchella
EFE.R.R Figueira
E.R.R Figueira
FMF.F Makdissi
F.F Makdissi
VRV Rocha-Santos
V Rocha-Santos
RMR.B Martino
R.B Martino
MMMarcel c c Machado
Marcel c c Machado

1 January 2021 in Clinics
Verified
Journal Article
Open access
LNLucas S. Nacif
Lucas S. Nacif
LZLeonardo Y. Zanini
Leonardo Y. Zanini
RPRafael S. Pinheiro
Rafael S. Pinheiro
DWDaniel Reis Waisberg
Daniel Reis Waisberg
VRVinicius Rocha-Santos
Vinicius Rocha-Santos
LCLuiz Carneiro-D’aLbuquerque
Luiz Carneiro-D’aLbuquerque
Non-tumoral portal vein thrombosis (PVT) is associated with higher morbidity and mortality in liver transplantation (LT). In this study, we aimed to evaluate the impact of PVT in LT outcomes and analyze the types of surgical techniques used for dealing ...

9 November 2020 in Liver Transplantation
Verified
Journal Article
Open access
PDF file
DWDaniel Reis Waisberg
Daniel Reis Waisberg
EAEdson Abdala
Edson Abdala
LNLucas Souto Nacif
Lucas Souto Nacif
LDLiliana Ducatti
Liliana Ducatti
LHLuciana Bertocco Haddad
Luciana Bertocco Haddad
LCLuiz Augusto Carneiro‐D’aLbuquerque
Luiz Augusto Carneiro‐D’aLbuquerque
We read with interest Massoumi et al.’s article(1) regarding 5 patients who developed coronavirus disease 2019 (COVID‐19) in the early postoperative period of liver transplantation (LT). None of them exhibited severe disease and they all fully recovered, suggesting that COVID‐19 in the early postoperative period of LT might not be associated with unfavorable outcomes. Here, we share our experience with 7 cases, which was not so promising.

1 May 2004 in Transplantation Proceedings
Verified
Journal Article
Closed access
DMD.M Medeiros
D.M Medeiros
Ana Cristina Mendes-OliveiraAna Cristina Mendes-Oliveira
Ana Cristina Mendes-Oliveira
MBM.F.A Barros
M.F.A Barros
RCR.A Cury
R.A Cury
HSH Sette-Junior
H Sette-Junior
MMMarcel c c Machado
Marcel c c Machado

24 March 2022 in Transplantation Proceedings
Verified
Journal Article
Closed access
VRVinicius Rocha-Santos
Vinicius Rocha-Santos
RARubens Macedo Arantes
Rubens Macedo Arantes
DWDaniel Reis Waisberg
Daniel Reis Waisberg
CPCarlos Andres Pantanali
Carlos Andres Pantanali
RPRafael Soares Pinheiro
Rafael Soares Pinheiro
LCLuiz Augusto Carneiro-D'ALbuquerque
Luiz Augusto Carneiro-D'ALbuquerque